Recurrent idiopathic membranous nephropathy: Early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies

American Journal of Transplantation

Volumn 9, Issue 12, 2009, Pages 2800-2807

  El Zoghby, Ziad M ^a   Grande, Joseph P ^a   Fraile, M G ^a   Norby, S M ^a   Fervenza, F C ^a   Cosio, F G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Kidney transplantation; Membranous glomerulonephritis; Recurrent glomerulonephritis; Therapy

Indexed keywords

RITUXIMAB;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IMMUNE COMPLEX DEPOSITION; INCIDENCE; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; REMISSION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BIOPSY; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECURRENCE;

EID: 72449168392     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02851.x     Document Type: Article

References (27)

1. USRDS 2006. Annual data report. Am J Kidney Dis the official journal of the National Kidney Foundation 2007 49 : S1 S234.
2. Maisonneuve P, Agodoa L, Gellert R et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: Results from an international comparative study. Am J Kidney Dis 2000 35 : 157 165.
3. El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009 9 : 527 535.
4. Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int 2001 59 : 1983 1994.
5. Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy [see comment]. New Engl J Med 1993 329 : 85 89.
6. Donadio JV Jr., Torres VE, Velosa JA et al. Idiopathic membranous nephropathy: The natural history of untreated patients. Kidney Int 1988 33 : 708 715.
7. Dabade TS, Grande JP, Norby SM, Fervenza FC, Cosio FG. Recurrent idiopathic membranous nephropathy after kidney transplantation: A surveillance biopsy study. Am J Transplant 2008 8 : 1318 1322.
8. Ruggenenti P, Chiurchiu C, Brusegan V et al. Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 2003 14 : 1851 1857.
9. Fervenza FC, Cosio FG, Erickson SB et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008 73 : 117 125.
10. Ruggenenti P, Cravedi P, Sghirlanzoni MC et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 2008 3 : 1652 1659.
11. Weclawiak H, Ribes D, Guilbeau-Frugier C et al. Relapse of membranous glomerulopathy after kidney transplantation: Sustained remittance induced by rituximab. Clin Nephrol 2008 69 : 373 376.
12. Gallon L, Chhabra D. Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am J Transplant 2006 6 : 3017 3021.
13. Cosio FG, Grande JP, Larson TS et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005 5 : 1130 1136.
14. Cosio FG, Amer H, Grande JP, Larson TS, Stegall MD, Griffin MD. Comparison of low versus high tacrolimus levels in kidney transplantation: Assessment of efficacy by protocol biopsies. Transplantation 2007 83 : 411 416.
15. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 2001 59 : 1484 1490.
16. Ruggenenti P, Chiurchiu C, Abbate M et al. Rituximab for idiopathic membranous nephropathy: Who can benefit? Clin J Am Soc Nephrol 2006 1 : 738 748.
17. Remuzzi G, Schieppati A, Garattini S. Treatment of idiopathic membranous glomerulopathy. Curr Opin Nephrol Hypertens 1994 3 : 155 163.
18. Cattran D. Management of membranous nephropathy: When and what for treatment. J Am Soc Nephrol %R 101681/ASN2005010028 2005 16 : 1188 1194.
19. Ponticelli C. Membranous nephropathy. J Nephrol 2007 20 : 268 287.
20. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: Diagnosis and treatment. Clin J Am Soc Nephrol: CJASN 2008 3 : 905 919.
21. Schieppati A, Perna A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev 2004 : CD004293.
22. Ambalavanan S, Fauvel JP, Sibley RK, Myers BD. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol 1996 7 : 290 298.
23. Ponticelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998 9 : 444 450.
24. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995 48 : 1600 1604.
25. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States [see comment]. Am J Transplant 2004 4 : 905 913.
26. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002 360 : 923 924.
27. Beck LH Jr., Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. New Engl J Med 2009 361 : 11 21.